Blog
RSS FeedPosted by Michael Wonder on 27 Apr 2026
Price feud over Mounjaro denies Australians access to cheaper diabetes and weight loss drug
24 April 2026 - Hundreds of thousands of Australians with type 2 diabetes mellitus could miss out on access to ...
Posted by Michael Wonder on 27 Apr 2026
Novartis Rhapsido receives European Commission approval as first oral targeted treatment for chronic spontaneous urticaria
27 April 2026 - Novartis announced today that the European Commission approved Rhapsido (remibrutinib) for chronic spontaneous urticaria in adult patients ...
Posted by Michael Wonder on 25 Apr 2026
Highlights from 20-23 April 2026 CHMP meeting
24 April 2026 - The EMA’s CHMP recommended five medicines for approval at its April 2026 meeting. ...
Posted by Michael Wonder on 25 Apr 2026
Bristol Myers Squibb and Pfizer to make Eliquis (apixaban) available via Mark Cuban Cost Plus Drug Company
24 April 2026 - Expands Options for Cash-Paying Patients to Access the Nation’s #1 Prescribed Oral Blood Thinner ...
Posted by Michael Wonder on 25 Apr 2026
‘Unviable’: 450,000 Australians to miss out on subsidised weight loss drug
24 April 2026 - An estimated 450,000 Australians will miss out on discounted weight loss medication after pharmaceutical giant Eli ...
Posted by Michael Wonder on 25 Apr 2026
Novartis withdraws EMA application for adding new indication for Pluvicto
24 April 2026 - Novartis has withdrawn a EMA type II variation application for Pluvicto to treat adult patients with prostate-specific ...
Posted by Michael Wonder on 25 Apr 2026
Belite Bio initiates rolling submission of new drug application to the US FDA for tinlarebant for the treatment of Stargardt disease
21 April 2026 - Belite expects to complete the new drug application submission in the second quarter of 2026. ...
Posted by Michael Wonder on 25 Apr 2026
Grace Therapeutics provides regulatory update on new drug application for GTx-104
23 April 2026 - Grace Therapeutics today announced that the US FDA has issued a complete response letter for the Company’s ...
Posted by Michael Wonder on 25 Apr 2026
Drug company Lilly refuses to list Mounjaro on PBS, says price too low
24 April 2026 - Drug company Eli Lilly has refused to place Mounjaro on the PBS despite the regulator recommending ...
Posted by Michael Wonder on 25 Apr 2026
Arrowhead Pharmaceuticals receives positive CHMP opinion recommending approval of Redemplo (plozasiran) to reduce triglycerides in adults with familial chylomicronaemia syndrome in Europe
24 April 2026 - The CHMP opinion is based on positive results from the Phase 3 PALISADE study where Redemplo ...
Posted by Michael Wonder on 25 Apr 2026
FDA accelerates action on treatments for serious mental illness following executive order
24 April 2026 - Agency issues priority vouchers, clears new clinical research, and advances guidance to support treatments for depression, PTSD, ...
Posted by Michael Wonder on 25 Apr 2026
‘Diffficult to see’ Mounjaro funded for weight loss, says pharma as diabetes stoush erupts
25 April 2026 - The weight loss drug has finally been recommended for public funding for those with diabetes, but manufacturers ...
Posted by Michael Wonder on 25 Apr 2026
Public summary documents – December 2025 PBAC meeting
24 April 2026 - The Public summary documents from the December 2025 PBAC meeting are now available. ...
Posted by Michael Wonder on 25 Apr 2026
Recommendations made by the PBAC – March 2026
24 April 2026 - Recommendations made by the PBAC in March 2026 relating to the listing of medicines on the ...
Posted by Michael Wonder on 24 Apr 2026
EMA sees slight improvement in approval submission predictability, reversing trend
23 April 2026 - The trend for the timing of initial marketing authorisation applications to be less predictable is slowly reversing ...